Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Metrics to compare | DRUG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDRUGPeersSector | |
---|---|---|---|---|
P/E Ratio | −69.2x | −3.1x | −0.7x | |
PEG Ratio | 1.03 | 0.00 | 0.00 | |
Price/Book | 11.9x | 2.8x | 2.6x | |
Price / LTM Sales | - | 5.8x | 3.4x | |
Upside (Analyst Target) | −10.9% | 130.9% | 37.9% | |
Fair Value Upside | Unlock | 6.1% | 5.2% | Unlock |